2 June 2017 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Human papilloma virus (9 valent) (Gardasil 9)
  
• Aflibercept (Eylea)
  
• Ranibizumab (Lucentis)
  
• Bevacizumab (Avastin)
  
• Baricitinib (Olumiant)
  
• Indacaterol maleate with glycopyrronium bromide (Ultibro Breezhaler)
  

Read TC agenda [French]